Latest news with #LeeRothBurnsMcClellanPhone
Yahoo
06-03-2025
- Business
- Yahoo
Altimmune to Host Virtual R&D Day on March 13, 2025
Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA GAITHERSBURG, M.D., March 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. The event will include presentations from renowned Key Opinion Leaders (KOLs) in obesity, MASH and each of the two additional indications, covering the scientific rationale for pemvidutide in each indication, clinical data generated to-date and plans for the continued development of pemvidutide, including the upcoming topline data readout from IMPACT, the Company's Phase 2b trial in MASH, which is expected in the second quarter of 2025. The event will be available at and via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications. For more information, please visit Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@ Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@ Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: This press release was published by a CLEAR® Verified in to access your portfolio
Yahoo
03-03-2025
- Business
- Yahoo
Altimmune to Participate in the Leerink Global Healthcare Conference
GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows: Conference: Leerink Global Healthcare Conference Date/Time: Monday, March 10, 2025, at 3:40 p.m. EST The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@ Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@ Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: This press release was published by a CLEAR® Verified in to access your portfolio
Yahoo
29-01-2025
- Business
- Yahoo
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows: Conference: Guggenheim SMID Cap Biotech Conference Date/Time: Wednesday, February 5, 2025, at 9:30 a.m. EST The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@ Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@ Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: in to access your portfolio
